PMID- 30711987
OWN - NLM
STAT- MEDLINE
DCOM- 20190220
LR  - 20211204
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 39
IP  - 2
DP  - 2019 Feb
TI  - Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal 
      Cell Carcinoma Outpatients Treated with Pazopanib.
PG  - 999-1004
LID - 10.21873/anticanres.13205 [doi]
AB  - BACKGROUND: Pazopanib is an effective treatment option for renal cell carcinoma 
      (RCC). However, the therapy is often limited by the appearance of adverse events 
      (AEs), including nausea/vomiting, hepatic impairment, hand-foot syndrome, 
      diarrhea, hypertension and oral mucositis. Early management of AEs is, therefore, 
      extremely important in order to maximize treatment outcomes. PATIENTS AND 
      METHODS: This non-randomized controlled before-and-after study was carried out to 
      evaluate the effectiveness of our comprehensive pharmaceutical interventions in 
      37 outpatients receiving pazopanib for RCC (experimental group). Data were 
      compared with those obtained from 13 patients before the start of pharmaceutical 
      intervention (control group). RESULTS: The incidence rates of grade 2 or more 
      nausea and anorexia were significantly lower in the experimental, than in the 
      control group (3% versus 38% for nausea, respectively, p=0.003; 8% versus 46% for 
      anorexia, respectively, p=0.005). Importantly, non-adherence based on patient 
      self-assessment was not observed with intervention (0% versus 38%, p<0.001). 
      Consequently, the median total dose of pazopanib was increased by the 
      intervention (72,600 versus 18,200 mg, p=0.002). Moreover, the median time to 
      treatment failure was significantly longer with intervention than before (10.2 
      versus 1.7 months, HR=0.23, 95% CI=0.110-0.499, p<0.001). These findings suggest 
      that our interventions are highly effective for enhancing treatment outcomes.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Todo, Maki
AU  - Todo M
AD  - Department of Pharmacy, International Medical Center, Saitama Medical University, 
      Saitama, Japan m_todo@saitama-med.ac.jp.
FAU - Shirotake, Suguru
AU  - Shirotake S
AD  - Department of Uro-Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Nishimoto, Koshiro
AU  - Nishimoto K
AD  - Department of Uro-Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Yasumizu, Yota
AU  - Yasumizu Y
AD  - Department of Uro-Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Kaneko, Gou
AU  - Kaneko G
AD  - Department of Uro-Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Kondo, Hideyuki
AU  - Kondo H
AD  - Department of Uro-Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Okabe, Takashi
AU  - Okabe T
AD  - Department of Uro-Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Makabe, Hideki
AU  - Makabe H
AD  - Department of Pharmacy, International Medical Center, Saitama Medical University, 
      Saitama, Japan.
FAU - Oyama, Masafumi
AU  - Oyama M
AD  - Department of Uro-Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Indazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 7RN5DR86CK (pazopanib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*adverse effects
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Indazoles
MH  - Kaplan-Meier Estimate
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - *Neoplasm Metastasis
MH  - Outpatients
MH  - Patient Compliance
MH  - Pyrimidines/*adverse effects
MH  - Self Report
MH  - Sulfonamides/*adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Pazopanib
OT  - adverse events
OT  - metastasis
OT  - pharmaceutical care
OT  - renal cell carcinoma
EDAT- 2019/02/04 06:00
MHDA- 2019/03/21 06:00
CRDT- 2019/02/04 06:00
PHST- 2018/12/15 00:00 [received]
PHST- 2019/01/11 00:00 [revised]
PHST- 2019/01/16 00:00 [accepted]
PHST- 2019/02/04 06:00 [entrez]
PHST- 2019/02/04 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
AID - 39/2/999 [pii]
AID - 10.21873/anticanres.13205 [doi]
PST - ppublish
SO  - Anticancer Res. 2019 Feb;39(2):999-1004. doi: 10.21873/anticanres.13205.